Breaking News

Izana Initiates Namilumab Study in Worsening COVID-19

Compassionate use study of monoclonal antibody therapy will be evaluated in rapidly worsening COVID-19 patients in Italy

By: Contract Pharma

Contract Pharma Staff

Izana Bioscience has initiated a compassionate use study involving namilumab (IZN-101) in the treatment of patients with rapidly worsening COVID-19 in cooperation with the Humanitas research group. The study will take place in Bergamo and Milan, Italy.   Namilumab is the company’s wholly-owned, phase III-ready, fully human monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), currently in late-stage clinical development for the treatment of rheumatoid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters